难治性成人斯蒂尔病的生物治疗：一项单中心回顾性队列研究。
Biological treatment in resistant adult-onset Still's disease: A single-center, retrospective cohort study.
作者信息
Çolak Seda, Tekgöz Emre, Mammadov Maghrur, Çınar Muhammet, Yılmaz Sedat
机构信息
Department of Internal Medicine, Division of Rheumatology, Gülhane Training and Research Hospital, Ankara, Turkey.
出版信息
Arch Rheumatol. 2021 Jun 24;37(1):11-18. doi: 10.46497/ArchRheumatol.2022.8669. eCollection 2022 Mar.
OBJECTIVES
The aim of this study was to assess the demographic and clinical characteristics of patients with adult-onset Still's disease (AOSD) under biological treatment.
PATIENTS AND METHODS
This retrospective cohort study included a total of 19 AOSD patients (13 males, 6 females; median age: 37 years; range, 28 to 52 years) who received biological drugs due to refractory disease between January 2008 and January 2020. The data of the patients were obtained from the patient files. The response to the treatment was evaluated based on clinical and laboratory assessments at third and sixth follow-up visits.
RESULTS
Interleukin (IL)-1 inhibitor was prescribed for 13 (68.4%) patients and IL-6 inhibitor prescribed for six (31.6%) patients. Seventeen (89.5%) patients experienced clinical remission.
CONCLUSION
Biological drugs seem to be effective for AOSD patients who are resistant to conventional therapies. Due to the administration methods and the high costs of these drugs, however, tapering the treatment should be considered, after remission is achieved.
目的
本研究旨在评估接受生物治疗的成人斯蒂尔病（AOSD）患者的人口统计学和临床特征。
患者与方法
这项回顾性队列研究共纳入了19例AOSD患者（13例男性，6例女性；中位年龄：37岁；范围28至52岁），这些患者在2008年1月至2020年1月期间因难治性疾病接受了生物药物治疗。患者数据来自患者档案。根据第三次和第六次随访时的临床和实验室评估来评估治疗反应。
结果
13例（68.4%）患者使用了白细胞介素（IL）-1抑制剂，6例（31.6%）患者使用了IL-6抑制剂。17例（89.5%）患者实现了临床缓解。
结论
生物药物似乎对常规治疗耐药的AOSD患者有效。然而，由于这些药物的给药方式和高昂成本，在实现缓解后应考虑逐渐减少治疗。
Zotero 插件